Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
4.560
-0.030 (-0.65%)
Oct 15, 2025, 11:12 AM EDT - Market open
Adverum Biotechnologies Stock Forecast
Stock Price Forecast
The 4 analysts that cover Adverum Biotechnologies stock have a consensus rating of "Strong Buy" and an average price target of $19.75, which forecasts a 333.11% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $33.
Price Target: $19.75 (+333.11%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adverum Biotechnologies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +557.89% | Sep 23, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +623.68% | Aug 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +163.16% | Jun 26, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | -12.28% | May 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +623.68% | May 15, 2025 |
Financial Forecast
Revenue This Year
15.49M
from 1.00M
Increased by 1,449.40%
Revenue Next Year
307.02K
from 15.49M
Decreased by -98.02%
EPS This Year
-5.40
from -6.62
EPS Next Year
-1.84
from -5.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 78.8M | 948,150 | |||
| Avg | 15.5M | 307,020 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7,775.0% | -93.9% | |||
| Avg | 1,449.4% | -98.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.72 | -0.56 | |||
| Avg | -5.40 | -1.84 | |||
| Low | -7.44 | -3.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.